Research Studies on COPD Flare-Ups Now Available in Greater Houston, Greater Cincinnati, Rock Hill, Mooresville, and Wyomissing

BOSTON — (BUSINESS WIRE) — A new research study on chronic obstructive pulmonary disease (COPD) is now available in the Greater Houston, Texas, area for a potential treatment for reducing COPD exacerbations. The AERIFY-1 study from Sanofi will evaluate if the investigational treatment, itepekimab, reduces dangerous symptom flare-ups in former smokers with moderate-to-severe COPD. The study is offered at Care Access locations in Houston, Conroe, Lake Jackson, and Webster.

COPD, the sixth leading cause of death in the United States, is a serious and life-threatening lung disease that gets worse over time. People with COPD are likely to experience symptom flare-ups, called exacerbations, in which breathing problems worsen and can persist for several days. COPD exacerbations can require hospitalization and are associated with increased mortality. Although COPD is treatable with currently available therapies, there is a need for safer and more effective options.

“COPD can make everyday living very difficult and exacerbations of this disease may be life-threatening,” said Dr. Ali Bajwa, a Care Access Principal Investigator for this study. “This study seeks to better understand how to reduce the risk of exacerbation and help improve the quality of life of those with COPD.”

The research study is now enrolling for former smokers in Greater Houston who are 40 to 85 years old and have been diagnosed with moderate-to-severe COPD. To learn more about this study, visit joincopdstudy.com or contact Care Access at (351) 222-5112.

Care Access opened its doors in the Greater Houston area in collaboration with local community leaders and healthcare providers seeking to make clinical research more accessible. The convenient settings throughout the Houston area provide local residents the option to participate in clinical studies close to home.

BOSTON — (BUSINESS WIRE) — A new research study on chronic obstructive pulmonary disease (COPD) is now available in Hamilton and Middletown, Ohio, for a potential treatment for reducing COPD exacerbations. The AERIFY-1 study from Sanofi will evaluate if the investigational treatment, itepekimab, reduces dangerous symptom flare-ups in former smokers with moderate-to-severe COPD.

COPD, the sixth leading cause of death in the United States, is a serious and life-threatening lung disease that gets worse over time. People with COPD are likely to experience symptom flare-ups, called exacerbations, in which breathing problems worsen and can persist for several days. COPD exacerbations can require hospitalization and are associated with increased mortality. Although COPD is treatable with currently available therapies, there is a need for safer and more effective options.

“About one in thirteen adults in Butler County are living with COPD, which is concerning because that’s higher than the national average,” said Dr. Michael Gabrilovich, a Care Access Research Investigator for this study. “COPD flare-ups can cause further damage to the lungs, so it’s important to prevent them, if possible.”

The research study is now enrolling for former smokers who are 40 to 85 years old and have been diagnosed with moderate-to-severe COPD. To learn more about this study, visit joincopdstudy.com or contact Care Access at (351) 222-5112.

Care Access opened its doors in the Greater Cincinnati area in collaboration with local community leaders and healthcare providers seeking to make clinical research more accessible. The local setting provides residents of Hamilton, Middletown, and surrounding communities the option to participate in clinical studies without traveling into the city.

BOSTON — (BUSINESS WIRE) — A new research study on chronic obstructive pulmonary disease (COPD) is now available in Rock Hill, S.C., for a potential treatment for reducing COPD exacerbations. The AERIFY-2 study from Sanofi will evaluate if the investigational treatment, itepekimab, reduces dangerous symptom flare-ups in both current and former smokers with moderate-to-severe COPD.

COPD, the sixth leading cause of death in the United States, is a serious and life-threatening lung disease that gets worse over time. People with COPD are likely to experience symptom flare-ups, called exacerbations, in which breathing problems worsen and can persist for several days. COPD exacerbations can require hospitalization and are associated with increased mortality. Although COPD is treatable with currently available therapies, there is a need for safer and more effective options.

“Approximately one in fourteen adults in South Carolina have COPD, which is higher than the national average,” said Dr. Arun Adlakha, the Care Access Research Investigator for this study in Rock Hill. “Offering this study here locally makes it convenient for those in our community who want to join.”

The research study is now enrolling for current and former smokers who are 40 to 85 years old and have been diagnosed with moderate-to-severe COPD. To learn more about this study, visit joincopdstudy.com or contact Care Access at (351) 222-5112.

Care Access opened its doors in Rock Hill in collaboration with local community leaders and healthcare providers seeking to make clinical research more accessible. The community-based setting provides Rock Hill residents the option to participate in clinical studies close to home.

BOSTON — (BUSINESS WIRE) — A new research study on chronic obstructive pulmonary disease (COPD) is now available in Mooresville, N.C., for a potential treatment for reducing COPD exacerbations. The AERIFY-2 study from Sanofi will evaluate if the investigational treatment, itepekimab, reduces dangerous symptom flare-ups in both current and former smokers with moderate-to-severe COPD.

COPD, the sixth leading cause of death in the United States, is a serious and life-threatening lung disease that gets worse over time. People with COPD are likely to experience symptom flare-ups, called exacerbations, in which breathing problems worsen and can persist for several days. COPD exacerbations can require hospitalization and are associated with increased mortality. Although COPD is treatable with currently available therapies, there is a need for safer and more effective options.

“In Iredell County, COPD causes over 100 deaths per year on average,” said Dr. Sever Surdulescu, the Care Access Research Investigator for this study in Mooresville. “Finding new ways to reduce or prevent COPD exacerbations would significantly benefit those who are living with this condition.”

The research study is now enrolling for current and former smokers who are 40 to 85 years old and have been diagnosed with moderate-to-severe COPD. To learn more about this study, visit joincopdstudy.com or contact Care Access at (351) 222-5112.

Care Access opened its doors in Mooresville in collaboration with local community leaders and healthcare providers seeking to make clinical research more accessible. The local setting provides residents of Mooresville and surrounding communities the option to participate in clinical studies without traveling into the city.

BOSTON — (BUSINESS WIRE) — A new research study on chronic obstructive pulmonary disease (COPD) is now available in Wyomissing, Pa., for a potential treatment for reducing COPD exacerbations. The AERIFY-2 study from Sanofi will evaluate if the investigational treatment, itepekimab, reduces dangerous symptom flare-ups in both current and former smokers with moderate-to-severe COPD.

COPD, the sixth leading cause of death in the United States, is a serious and life-threatening lung disease that gets worse over time. People with COPD are likely to experience symptom flare-ups, called exacerbations, in which breathing problems worsen and can persist for several days. COPD exacerbations can require hospitalization and are associated with increased mortality. Although COPD is treatable with currently available therapies, there is a need for safer and more effective options.

“About seven percent of adults in Pennsylvania are living with COPD, and Berks County has a higher rate of COPD-related hospitalization than other parts of the state,” said Dr. Alec Platt, the Care Access Research Investigator for this study in Wyomissing. “Having access to this global study here in Wyomissing is an important opportunity for local residents dealing with this condition.”

The research study is now enrolling for current and former smokers who are 40 to 85 years old and have been diagnosed with moderate-to-severe COPD. To learn more about this study, visit joincopdstudy.com or contact Care Access at (351) 222-5112.

Care Access opened its doors in Wyomissing in collaboration with local community leaders and healthcare providers seeking to make clinical studies more easily accessible to patients. The local setting provides residents of Wyomissing, Reading, and surrounding communities the option to participate in clinical studies close to home.